Infection Prevention Endotracheal Tube

The Bactiguard Infection Protection Endotracheal Tubes (BIP ETT and BIP ETT Evac), with the Bactiguard coating, reduces the risk of microbial adhesion, colonization and subsequent respiratory infections. It is available both with and without subglottic secretion drainage (SSD), a mechanical feature in itself proven to reduce the risk of ventilator associated pneumonia (VAP). Bactiguard coated ETTs have been shown to effectively reduce microbial adhesion to the device by up to 98% in microbiological in vitro studies with relevant clinical isolate strains3. In addition, a clinical study on 100 patients comparing a standard uncoated endotracheal tube with BIP ETT concluded that the Bactiguard coating reduced the incidence of VAP by 67%4. The combination of subglottic secretion drainage and the unique Bactiguard coating on the new tube, BIP ETT Evac, is designed to offer the best protection against VAP available on the market.
 

The BIP ETT is intended for use in airway management by oral or nasal intubation of the trachea. It is used to secure an open airway during anesthesia or when intubation is necessary as part of standard medical care. The beveled tip, Murphy Eye and high volume-low pressure cuff are designed to minimize the risk of damages to the patients’ trachea and ensure safe usage. The catheter is made of PVC and coated with the Bactiguard coating on both the inside and outside of the tube, and can be used up to 30 days.
 

Ventilator Associated Pneumonia (VAP)

VAP is a common and very serious healthcare associated infection (HAI) of the respiratory tract that can affect patients using certain medical devices, such as ETTs. Microbial adhesion on the tube itself, resulting in bio­film formation is one major cause of infection. In long-term ventilated patients subglottic secretions can accumulate above the cuff of the ETT and hence, represent an ideal growth medium for bacteria. By microaspiration along the cuff, these contaminated secretions might pass into the lower respiratory tract and become a potential cause of lower airway infec­tion, including VAP.

VAP is the second most common nosocomial infec­tion in the ICU, and estimated to occur in up to 25% of patients.5-7 It is associated with increasing the num­ber of days the patients need to stay in the hospital by up to 25 days8.

Late-onset VAP is often associated with high-risk pathogens such as MRSA and is associated with a greater negative impact on patient outcomes and hospital cost.9 Mortality that is directly attributable to VAP is estimated to be as high as 30-50 %.10-11

In addition, many of these infections are treated with antibiotics, which increase the risk of emergence and spread of multi-resistant microbes. WHO estimates that antimicrobial resistance is so serious that it threatens the achievements of modern medicine.2
 

Contact me, I want to know more

I want to order and I am interested in knowing more about Bactiguard’s products

clinically proven effective against infections

In a clinical study on 100 patients comparing a standard uncoated endotracheal tube with the BIP ETT, it was concluded that the coating reduced the incidence of ventilator associated pneumonia by 67% (OR 3.42; p=0.14)4. This prospective, randomized and independent investigation included toxicological intensive care patients suffering from poisoning. In addition to the infection rate, length of hospital stay as well as antibiotic use was also monitored. The BIP ETT group used significantly less antibiotics (OR 0.3, p=0.05) and stayed in hospital 2 days less in average (18 and 16 days, respectively).

Tissue-friendly and safe technology

The Bactiguard solution is unique, tissue friendly and safe for patient use. As opposed to other coating technologies, which depend on the release of substances, which kill bacteria,  e.g. large amounts of silver ions, chlorhexidine or antibiotics, the Bactiguard coating is neither toxic nor pharmacologic.12 The Bactiguard coated BIP ETTs have a strong biocompatibility profile.

They have been shown non-toxic to cells, non-irritant to mucosa and not-sensitizing to allergic reactions.13 It does not damage human mucosa and does not give adverse events in patients.14
 

Referenser

1. Klevens RM et al, Public Health Rep. 2007 Mar-Apr;122(2):160-6
2. Antimicrobial resistance, Global report on surveillance, WHO
3. Data on file
4 Tincu R, Poster Euroanasthesia 2015
5. Ibrahim EH et al. Chest. 2001;120(2):555-561.
6. Craven DE et al. Infect. 1996;11(1):32-53.
7. Rello J et al. Chest. 2002;122(6):2115-2121.
8 Warren DK et al. Crit Care Med. 2003;31(5):1312-1317.
9. Kollef MH et al. Chest.1995;108(6):1655-1662.
10. Kollef MH et al. Chest. 2005; 128 (6): 3854-3862.
11. Stijn Blot et al. Critcal Care Medicine, March (2014) 42:3
12 Data on file.
13 Data on file.
14.  Björling et al. BMC Anesthesiology (2015) 15:174
 

Article nr Article Inner Ø (mm) Outer Ø (mm) Length (mm)
31VC06010 Oral with HVLP* cuff and SSD 6,0 9,0 280
31VC06510 Oral with HVLP* cuff and SSD 6,5 9,8 290
31VC07010 Oral with HVLP* cuff and SSD 7,0 10,4 300
31VC07510 Oral with HVLP* cuff and SSD 7,5 11,2 310
31VC08010 Oral with HVLP* cuff and SSD 8,0 11,8 320
31VC08510 Oral with HVLP* cuff and SSD 8,5 12,6 320
31VC09010 Oral with HVLP* cuff and SSD 9,0 13,1 320
See more [+]
See less [-]
Article nr Article Inner Ø (mm) Outer Ø (mm) Length (mm)
311005010 Oral/Nasal with HVLP* cuff 5,0 6,9 240
311005510 Oral/Nasal with HVLP* cuff 5,5 7,5 270
311006010 Oral/Nasal with HVLP* cuff 6,0 8,2 280
311006510 Oral/Nasal with HVLP* cuff 6,5 8,8 290
311007010 Oral/Nasal with HVLP* cuff 7,0 9,6 300
311007510 Oral/Nasal with HVLP* cuff 7,5 10,2 310
311008010 Oral/Nasal with HVLP* cuff 8,0 10,9 320
311008510 Oral/Nasal with HVLP* cuff 8,5 11,5 320
311009010 Oral/Nasal with HVLP* cuff 9,0 12,1 320
311009510 Oral/Nasal with HVLP* cuff 9,5 12,7 320
311010010 Oral/Nasal with HVLP* cuff 10,0 13,6 320
See more [+]
See less [-]
Related files

BIP ETT Product Brochure